An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.


Bonnefoi H., Biganzoli L., Mauriac L., Cufer T., Schaefer P., Atalay G., ...Daha Fazla

European journal of cancer (Oxford, England : 1990), cilt.39, ss.1277-83, 2003 (SCI-Expanded) identifier identifier identifier